AR013094A1 - Compuestos de urea n-sustituida,composicion farmaceutica y uso de dichos compuestos para preparar medicamentos - Google Patents

Compuestos de urea n-sustituida,composicion farmaceutica y uso de dichos compuestos para preparar medicamentos

Info

Publication number
AR013094A1
AR013094A1 ARP980102858A ARP980102858A AR013094A1 AR 013094 A1 AR013094 A1 AR 013094A1 AR P980102858 A ARP980102858 A AR P980102858A AR P980102858 A ARP980102858 A AR P980102858A AR 013094 A1 AR013094 A1 AR 013094A1
Authority
AR
Argentina
Prior art keywords
hydrogen
compounds
alkyl
independently selected
represent
Prior art date
Application number
ARP980102858A
Other languages
English (en)
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR013094A1 publication Critical patent/AR013094A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP980102858A 1997-06-17 1998-06-16 Compuestos de urea n-sustituida,composicion farmaceutica y uso de dichos compuestos para preparar medicamentos AR013094A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87704997A 1997-06-17 1997-06-17

Publications (1)

Publication Number Publication Date
AR013094A1 true AR013094A1 (es) 2000-12-13

Family

ID=25369144

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102858A AR013094A1 (es) 1997-06-17 1998-06-16 Compuestos de urea n-sustituida,composicion farmaceutica y uso de dichos compuestos para preparar medicamentos

Country Status (14)

Country Link
EP (1) EP0989979A1 (https=)
JP (1) JP2002506444A (https=)
KR (1) KR20010013881A (https=)
CN (1) CN1267291A (https=)
AR (1) AR013094A1 (https=)
AU (1) AU8253598A (https=)
CA (1) CA2293706C (https=)
CO (1) CO4940458A1 (https=)
HU (1) HUP0002954A3 (https=)
IL (1) IL133389A0 (https=)
NZ (1) NZ501571A (https=)
PE (1) PE82799A1 (https=)
WO (1) WO1998057948A1 (https=)
ZA (1) ZA985205B (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
EP1322334A2 (en) * 2000-10-05 2003-07-02 George Q. Daley Methods of inducing cancer cell death and tumor regression
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
EP1695961A4 (en) * 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
CA2904393A1 (en) * 2013-03-15 2014-09-25 Araxes Pharma Llc Covalent inhibitors of kras g12c
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
JP2017528498A (ja) 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Kras g12c変異体タンパク質のインヒビター
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356351A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
CN110869357A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 化合物及其用于治疗癌症的使用方法
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
CN111960990A (zh) * 2020-07-23 2020-11-20 宿迁联盛科技股份有限公司 一种助剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
IL125062A (en) * 1995-12-22 2003-11-23 Schering Corp Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases
JP2001500508A (ja) * 1996-09-13 2001-01-16 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼの阻害に有用な置換ベンゾシクロヘプタピリジン誘導体
ES2234036T3 (es) * 1996-09-13 2005-06-16 Schering Corporation Compuestos utiles para inhibir la farnesil-protein-transferasa.

Also Published As

Publication number Publication date
HUP0002954A3 (en) 2002-11-28
AU8253598A (en) 1999-01-04
JP2002506444A (ja) 2002-02-26
PE82799A1 (es) 1999-08-26
KR20010013881A (ko) 2001-02-26
NZ501571A (en) 2002-02-01
HUP0002954A2 (hu) 2001-06-28
ZA985205B (en) 1998-12-15
IL133389A0 (en) 2001-04-30
EP0989979A1 (en) 2000-04-05
CO4940458A1 (es) 2000-07-24
CN1267291A (zh) 2000-09-20
WO1998057948A1 (en) 1998-12-23
CA2293706C (en) 2008-11-18
CA2293706A1 (en) 1998-12-23

Similar Documents

Publication Publication Date Title
AR013094A1 (es) Compuestos de urea n-sustituida,composicion farmaceutica y uso de dichos compuestos para preparar medicamentos
DK0650476T3 (da) Perifert, vasodilaterende middel, der indeholder N-acylerede 4-aminopiperidinderivater som aktive bestanddele
TR199902203T2 (xx) Fernesil transferaz engelleyici, N-veya C-ba�lant�l� imidazoller ile ikame edilmi� 1,8-anele kinolinon t�revleri.
DK365184D0 (da) 1,8-naphthyridinderivater eller estre eller salte deraf, deres fremstilling og anvendelse som farmaceutika
CO4650042A1 (es) Derivados de 6-fenilpiridil-2-amina
AR003936A1 (es) Compuestos triciclicos y composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento util para inhibir elcrecimiento anormal de celulas.
PE20011001A1 (es) Compuestos heterociclicos como inhibidores del intercambio de sodio/protones
ES2195034T3 (es) Inhibidor de metaloproteinasas, composicion farmaceutica que contiene este inhibidor y su utilizacion farmaceutica, y procedimientos que sirven para su preparacion.
ES2196772T3 (es) Compuestos amino ciclicos.
AR025276A1 (es) El uso de un compuesto que es un derivado de 2-amino-1,3-tiazol, un compuesto que es un derivado de 2-amino-1,3-tiazol, un procedimiento para producirlo y una composicion farmaceutica que lo comprende
CO5570660A2 (es) Indazolilpirrolotriazinas c-6 modificadas
ES2196806T3 (es) Derivados de fenilurea y de feniltiourea.
ES2150577T3 (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
DK0928788T3 (da) Imidazolidin-4-on-derivater, der er nyttige som anticancer-midler
FR2599740B1 (fr) Derives de benzo(b)thiophene de benzo(b)furannecarboxamides, leurs procedes de preparation et les medicaments les contenant
AR020165A1 (es) Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos
BR9811557A (pt) Derivados do 2-)4-aril ou heteroaril-piperazin-1-ilmetil)-1h-indol
DK39286A (da) Imidazolderivater, fremgangsmaade til fremstilling heraf og farmaceutiske praeparater indeholdende disse derivater
AR019674A1 (es) Compuestos antitromboticos y composiciones farmaceuticas que los contienen
PE20040750A1 (es) Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3
ES2094146T3 (es) Derivados de la piridazina, procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2090024T3 (es) Compuestos de cefemo y procedimientos para su preparacion.
AR027578A1 (es) Derivados de indano
MX9603998A (es) Agonista receptor de 5-ht3, derivado de tiazol novedoso e intermediario del mismo.
ES2160726T3 (es) Derivados de piperazin-2,5-diona como moduladores de resistencia a multiples farmacos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure